ClinicalTrials.gg
CompletedNCT01747928Updated May 2, 2014Results posted

Users Study Of The Caverject Delivery System

An Early Phase 1 interventional study of dual-chamber syringe in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-02.

Sponsored by Pfizer · Early Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
48
Ages
40 Years to 70 Years
Sex
Male
01

Study summary

Usability testing of the dual-chambered syringe in conjunction with the proposed patient instructions for use.

Read the detailed description

Usability testing of the dual-chambered syringe in conjunction with the proposed patient instructions for use

02

Conditions studied

  • Healthy

Keywords

  • usability study
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males

Exclusion criteria

Exclusion Criteria:

  • Inability to read English;
  • physical limitations preventing participant from operating the syringe
05

Study design

Phase
Early Phase 1
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Group 1

    Other: dual-chamber syringe

Interventions

  • Otherdual-chamber syringe

    dual-chamber syringe for mock injection

06

What researchers measure

Primary outcomes

  1. Delivery System Success Rate (DSSR)

    DSSR was defined as percentage of participants who were able to successfully expel the selected dose from the Caverject Impulse Dual Chamber Delivery System when relying on the modified Instructions for Use (IFU). The process was considered successful if the attempt was observed and documented by study personnel AND the participant didn't receive any operational/"hands on" demonstration on how to operate the plunger from study personnel AND after performing all preparatory steps, the participant was able to expel the dose to the selected plunger stop-point without any unexpected interruption.

    Time frame: Day 1

Secondary outcomes

  1. Number of Participants With Categorical Responses to the Participant Assessment Tool (PAT): Instructions Provided Were Useful?

    Participant responses were reported as follows: Very Useful, Somewhat Useful, Not Very Useful, Not Useful At All.

    Time frame: Day 1

  2. Number of Participants With Categorical Responses to the PAT: Instructions Provided Were Clear?

    Participant responses were reported as follows: Very clear, Somewhat clear, Not very clear, Not clear at all.

    Time frame: Day 1

  3. Number of Participants With Categorical Responses to the PAT: Most Difficult Step?

    Participant responses were reported as follows: No steps really difficult, Attaching needle, Mixing the solution, Getting the air out of syringe, Setting the dose, Pushing plunger, Other.

    Time frame: Day 1

  4. Number of Participants With Categorical Responses to the PAT: Syringe Easy to Use?

    Participant responses were reported as follows: Very easy, Somewhat easy, Somewhat difficult, Very difficult.

    Time frame: Day 1

  5. Number of Participants Providing Responses to Any Question on the PAT

    Number of participants providing responses on questions in the PAT. Questions were as follows: What step did you stop? Why?; Instructions provided were useful?; Instructions provided were clear?; Most difficult step?; Syringe easy to use?

    Time frame: Day 1

  6. Time Required to Perform Segments 1 to 5

    Steps involved while using the Caverject Impulse Delivery System were categorized into segments: Segment 1 (Assembly While Using the Caverject Impulse Delivery System), Segment 2 (Mixing the Solution), Segment 3 (De-aerating the Syring While Using the Caverject Impulse Delivery System), Segment 4 (Setting the Dose) and Segment 5 (Performing the Injection While Using the Caverject Impulse Delivery System).

    Time frame: Day 1

  7. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q1

    OAT, Q1: Participant assembled the components correctly. Observer responses were reported as follows: Yes, No. A "No" answer indicated failure according to the OAT. Q1 and Q2 made up Segment 1: Assembly of Components.

    Time frame: Day 1

  8. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q2

    OAT, Q2: Evidence of mechanical malfunction or defect for Segment 1. Observer responses were reported as follows: Yes, No. Q1 and Q2 made up Segment 1: Assembly of Components.

    Time frame: Day 1

  9. Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q3

    OAT, Q3: Participant performed mixing step correctly. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q3 to Q5 made up Segment 2: Mixing the Solution.

    Time frame: Day 1

  10. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q4

    OAT, Q4: Participant positioned piston correctly. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the SAP. Q3 to Q5 made up Segment 2: Mixing the Solution.

    Time frame: Day 1

  11. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q5

    OAT, Q5: Evidence of mechanical malfunction/defect for Segment 2. Observer responses were reported as follows: Yes, No. Q3 to Q5 made up Segment 2: Mixing the Solution.

    Time frame: Day 1

  12. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q6

    OAT, Q6: De-aeration step performed successfully. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.

    Time frame: Day 1

  13. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q7

    OAT, Q7: Participant depressed the plunger correctly to de-aerate the syringe. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the SAP. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.

    Time frame: Day 1

  14. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q8

    OAT, Q8: Evidence of mechanical malfunction/defect for Segment 3. Observer responses were reported as follows: Yes, No. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.

    Time frame: Day 1

  15. Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q9

    OAT, Q9: Participant was able to set a dose (any dose) for delivery. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q9 and Q10 made up Segment 4: Setting the Dose.

    Time frame: Day 1

  16. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q10

    OAT, Q10: Evidence of mechanical malfunction/defect for Segment 4. Observer responses were reported as follows: Yes, No. Q9 and Q10 made up Segment 4: Setting the Dose.

    Time frame: Day 1

  17. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q11

    OAT, Q11: Participant successfully set the correct dose (as assigned). Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

    Time frame: Day 1

  18. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q12

    OAT, Q12: Participant successfully expelled the dose into the target. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

    Time frame: Day 1

  19. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q13

    OAT, Q13: Was there any difficulty/obstruction encountered in expelling dose? Observer responses were reported as follows: Yes, No. A "Yes" response indicated failure according to the SAP. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

    Time frame: Day 1

  20. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q14b

    OAT, Q14b: Participant successfully expelled/injected the assigned dose (per Dose Card). Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

    Time frame: Day 1

  21. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q16

    OAT, Q16: Evidence of mechanical malfunction/defect. Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

    Time frame: Day 1

  22. Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q17

    OAT, Q17: Participant understood reason excess liquid was present after a partial-dose injection. Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

    Time frame: Day 1

07

Results

Posted May 2, 2014
Limitations and caveats
For outcome measure 7, the endpoint was originally the comments provided as part of the PAT. As clinicaltrials.gov do not support textual results, the number of participants who provided comments to any questions on the PAT are reported instead.

Participant flow

Participant flow — Overall Study
MilestoneCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Started66666666
Completed66666666
Not completed00000000

Outcome measures

PrimaryDelivery System Success Rate (DSSR)

DSSR was defined as percentage of participants who were able to successfully expel the selected dose from the Caverject Impulse Dual Chamber Delivery System when relying on the modified Instructions for Use (IFU). The process was considered successful if the attempt was observed and documented by study personnel AND the participant didn't receive any operational/"hands on" demonstration on how to operate the plunger from study personnel AND after performing all preparatory steps, the participant was able to expel the dose to the selected plunger stop-point without any unexpected interruption.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Delivery System Success Rate (DSSR)
percentage of participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose SettingAll Participants
Delivery System Success Rate (DSSR)66.67 (NA to NA)66.67 (NA to NA)100.00 (NA to NA)100.00 (NA to NA)100.00 (NA to NA)83.33 (NA to NA)100.00 (NA to NA)100.00 (NA to NA)89.58 (79.34 to 100.0)
Post-hocDSSR Based on the Primary Objective

This post-hoc DSSR was calculated in order to provide a DSSR that recognized as a "failure" only those participants who were unable to successfully complete the overall injection task, regardless of whether they met with difficulties at any step.

Time frame:
Day 1
Reported as:
Number · percentage of participants
DSSR Based on the Primary Objective
percentage of participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose SettingAll Participants
DSSR Based on the Primary Objective83.33 (NA to NA)83.33 (NA to NA)100.00 (NA to NA)100.00 (NA to NA)100.00 (NA to NA)83.33 (NA to NA)100.00 (NA to NA)100.00 (NA to NA)93.75 (84.63 to 100.0)
SecondaryNumber of Participants With Categorical Responses to the Participant Assessment Tool (PAT): Instructions Provided Were Useful?

Participant responses were reported as follows: Very Useful, Somewhat Useful, Not Very Useful, Not Useful At All.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants With Categorical Responses to the Participant Assessment Tool (PAT): Instructions Provided Were Useful?
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Very useful55656556
Somewhat useful01000100
Not very useful00010000
Not useful at all00000000
Missing answer10000010
SecondaryNumber of Participants With Categorical Responses to the PAT: Instructions Provided Were Clear?

Participant responses were reported as follows: Very clear, Somewhat clear, Not very clear, Not clear at all.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants With Categorical Responses to the PAT: Instructions Provided Were Clear?
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Very clear54666555
Somewhat clear02000111
Not very clear00000000
Not clear at all00000000
Missing answer10000000
SecondaryNumber of Participants With Categorical Responses to the PAT: Most Difficult Step?

Participant responses were reported as follows: No steps really difficult, Attaching needle, Mixing the solution, Getting the air out of syringe, Setting the dose, Pushing plunger, Other.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants With Categorical Responses to the PAT: Most Difficult Step?
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
No steps really difficult53456455
Attaching needle01210200
Mixing the solution00000000
Getting the air out of syringe00000000
Setting the dose00000001
Pushing plunger01000010
Other01000000
Missing answer10000000
SecondaryNumber of Participants With Categorical Responses to the PAT: Syringe Easy to Use?

Participant responses were reported as follows: Very easy, Somewhat easy, Somewhat difficult, Very difficult.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants With Categorical Responses to the PAT: Syringe Easy to Use?
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Very easy43566566
Somewhat easy13100100
Somewhat difficult00000000
Very difficult00000000
Missing answer10000000
SecondaryNumber of Participants Providing Responses to Any Question on the PAT

Number of participants providing responses on questions in the PAT. Questions were as follows: What step did you stop? Why?; Instructions provided were useful?; Instructions provided were clear?; Most difficult step?; Syringe easy to use?

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Providing Responses to Any Question on the PAT
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
What step did you stop? Why?11000100
Instructions provided were useful?56666656
Instructions provided were clear?56666666
Most difficult step?56666666
Syringe easy to use?56666666
SecondaryTime Required to Perform Segments 1 to 5

Steps involved while using the Caverject Impulse Delivery System were categorized into segments: Segment 1 (Assembly While Using the Caverject Impulse Delivery System), Segment 2 (Mixing the Solution), Segment 3 (De-aerating the Syring While Using the Caverject Impulse Delivery System), Segment 4 (Setting the Dose) and Segment 5 (Performing the Injection While Using the Caverject Impulse Delivery System).

Time frame:
Day 1
Reported as:
Mean · seconds
Time Required to Perform Segments 1 to 5
secondsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Segment 1 (n = 6, 6, 6, 6, 6, 6, 6, 6)148.8 ± 37.20189.3 ± 140.13176.0 ± 72.92194.3 ± 107.53246.5 ± 131.85168.2 ± 82.76142.3 ± 105.78144.5 ± 23.35
Segment 2 (n = 5, 6, 6, 6, 6, 5, 6, 6)47.2 ± 21.5373.0 ± 63.1142.3 ± 14.1953.8 ± 30.7353.8 ± 21.6850.2 ± 35.9064.2 ± 50.0339.5 ± 13.92
Segment 3 (n = 5, 6, 6, 6, 6, 5, 6, 6)49.2 ± 15.6960.2 ± 40.4171.8 ± 22.6979.5 ± 89.1755.8 ± 32.0342.6 ± 5.8643.2 ± 22.1363.3 ± 24.82
Segment 4 (n = 5, 5, 6, 6, 6, 5, 6, 6)34.4 ± 29.5537.4 ± 59.7729.0 ± 23.0830.0 ± 26.7120.0 ± 13.078.4 ± 6.3131.7 ± 24.2035.7 ± 16.50
Segment 5 (n = 5, 5, 6, 6, 6, 5, 6, 6)30.4 ± 17.0438.8 ± 53.6430.3 ± 17.7719.2 ± 11.9630.8 ± 15.2517.4 ± 13.2427.3 ± 20.3830.8 ± 17.51
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q1

OAT, Q1: Participant assembled the components correctly. Observer responses were reported as follows: Yes, No. A "No" answer indicated failure according to the OAT. Q1 and Q2 made up Segment 1: Assembly of Components.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q1
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes56666566
No (FAIL per OAT)10000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q2

OAT, Q2: Evidence of mechanical malfunction or defect for Segment 1. Observer responses were reported as follows: Yes, No. Q1 and Q2 made up Segment 1: Assembly of Components.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q2
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes00000000
No56666666
Excluded from Q210000000
SecondaryNumber of Participants Whom the Observer Had Categorical Responses to in the OAT: Q3

OAT, Q3: Participant performed mixing step correctly. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q3 to Q5 made up Segment 2: Mixing the Solution.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q3
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes56666566
No (FAIL per OAT)00000000
Did not participate10000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q4

OAT, Q4: Participant positioned piston correctly. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the SAP. Q3 to Q5 made up Segment 2: Mixing the Solution.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q4
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes56666566
No (FAIL per SAP)00000000
Did not participate10000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q5

OAT, Q5: Evidence of mechanical malfunction/defect for Segment 2. Observer responses were reported as follows: Yes, No. Q3 to Q5 made up Segment 2: Mixing the Solution.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q5
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes00000000
No56666566
Did not participate10000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q6

OAT, Q6: De-aeration step performed successfully. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q6
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes55666566
No (FAIL per OAT)01000000
Did not participate10000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q7

OAT, Q7: Participant depressed the plunger correctly to de-aerate the syringe. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the SAP. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q7
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes55666566
No (FAIL per SAP)00000000
Did not participate11000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q8

OAT, Q8: Evidence of mechanical malfunction/defect for Segment 3. Observer responses were reported as follows: Yes, No. Q6 to Q8 made up Segment 3: De-aeration of the Syringe.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q8
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes00000000
No55666566
Did not participate11000100
SecondaryNumber of Participants Whom the Observer Had Categorical Responses to in the OAT: Q9

OAT, Q9: Participant was able to set a dose (any dose) for delivery. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q9 and Q10 made up Segment 4: Setting the Dose.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Whom the Observer Had Categorical Responses to in the OAT: Q9
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes55666566
No (FAIL per OAT)00000000
Did not participate11000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q10

OAT, Q10: Evidence of mechanical malfunction/defect for Segment 4. Observer responses were reported as follows: Yes, No. Q9 and Q10 made up Segment 4: Setting the Dose.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q10
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes00000000
No55666566
Did not participate11000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q11

OAT, Q11: Participant successfully set the correct dose (as assigned). Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q11
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes55666566
No (FAIL per OAT)00000000
Did not participate11000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q12

OAT, Q12: Participant successfully expelled the dose into the target. Observer responses were reported as follows: Yes, No. A "No" response indicated failure according to the OAT. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q12
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes55666566
No (FAIL per OAT)00000000
Did not participate11000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q13

OAT, Q13: Was there any difficulty/obstruction encountered in expelling dose? Observer responses were reported as follows: Yes, No. A "Yes" response indicated failure according to the SAP. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q13
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes (FAIL per SAP)11000000
No44666566
Did not participate11000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q14b

OAT, Q14b: Participant successfully expelled/injected the assigned dose (per Dose Card). Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q14b
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes55666566
No00000000
Did not participate11000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q16

OAT, Q16: Evidence of mechanical malfunction/defect. Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q16
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes00000000
No55666566
Did not participate11000100
SecondaryNumber of Participants Which the Observer Had Categorical Responses to in the OAT: Q17

OAT, Q17: Participant understood reason excess liquid was present after a partial-dose injection. Observer responses were reported as follows: Yes, No. Q11 to Q17 made up Segment 5: Performing the Simulated Injection.

Time frame:
Day 1
Reported as:
Number · participants
Number of Participants Which the Observer Had Categorical Responses to in the OAT: Q17
participantsCaverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose Setting
Yes55606560
No00000000
Did not participate11000100
Not applicable (tested full dose)00060006

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Caverject 10 mcg Device - 2.5 mcg Dose Setting—0/6 (0%)0/6 (0%)
Caverject 10 mcg Device - 5 mcg Dose Setting—0/6 (0%)0/6 (0%)
Caverject 10 mcg Device - 7.5 mcg Dose Setting—0/6 (0%)0/6 (0%)
Caverject 10 mcg Device - 10 mcg Dose Setting—0/6 (0%)0/6 (0%)
Caverject 20 mcg Device - 5 mcg Dose Setting—0/6 (0%)0/6 (0%)
Caverject 20 mcg Device - 10 mcg Dose Setting—0/6 (0%)0/6 (0%)
Caverject 20 mcg Device - 15 mcg Dose Setting—0/6 (0%)0/6 (0%)
Caverject 20 mcg Device - 20 mcg Dose Setting—0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Caverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose SettingTotal
Mean53.0 ± 9.152.7 ± 10.051.3 ± 9.053.5 ± 9.063.0 ± 2.555.3 ± 4.857.8 ± 6.851.8 ± 5.654.8 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Caverject 10 mcg Device - 2.5 mcg Dose SettingCaverject 10 mcg Device - 5 mcg Dose SettingCaverject 10 mcg Device - 7.5 mcg Dose SettingCaverject 10 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 5 mcg Dose SettingCaverject 20 mcg Device - 10 mcg Dose SettingCaverject 20 mcg Device - 15 mcg Dose SettingCaverject 20 mcg Device - 20 mcg Dose SettingTotal
Female000000000
Male6666666648
08

Study locations

1 site
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2012
First posted
Dec 12, 2012
Start
Mar 2013
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
May 2, 2014
Last update
May 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01747928
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 12, 2012
Start date
Mar 2013
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
May 2, 2014
Last update
May 2, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion